JP2018526989A5 - - Google Patents

Info

Publication number

JP2018526989A5

JP2018526989A5 JP2018506260A JP2018506260A JP2018526989A5 JP 2018526989 A5 JP2018526989 A5 JP 2018526989A5 JP 2018506260 A JP2018506260 A JP 2018506260A JP 2018506260 A JP2018506260 A JP 2018506260A JP 2018526989 A5 JP2018526989 A5 JP 2018526989A5

Authority

JP

Japan

Prior art keywords

ser

glu

cys

asp

phe

Prior art date

2016-08-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 claims description 94
• 229920001184 polypeptide Polymers 0.000 claims description 93
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 93
• 230000004927 fusion Effects 0.000 claims description 86
• 102000017578 LAG3 Human genes 0.000 claims description 28
• 101150030213 Lag3 gene Proteins 0.000 claims description 28
• 150000001413 amino acids Chemical class 0.000 claims description 19
• 102000019298 Lipocalin Human genes 0.000 claims description 13
• 108050006654 Lipocalin Proteins 0.000 claims description 13
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
• 239000000203 mixture Substances 0.000 claims description 9
• 102000039446 nucleic acids Human genes 0.000 claims description 9
• 108020004707 nucleic acids Proteins 0.000 claims description 9
• 150000007523 nucleic acids Chemical class 0.000 claims description 9
• 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 8
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 8
• 238000000034 method Methods 0.000 claims description 7
• 230000035772 mutation Effects 0.000 claims description 7
• 125000000539 amino acid group Chemical group 0.000 claims description 6
• 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 claims description 5
• 239000012634 fragment Substances 0.000 claims description 4
• 230000000259 anti-tumor effect Effects 0.000 claims description 3
• 230000000694 effects Effects 0.000 claims description 3
• 230000002401 inhibitory effect Effects 0.000 claims description 3
• 210000004698 lymphocyte Anatomy 0.000 claims description 3
• 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
• 108060003951 Immunoglobulin Proteins 0.000 claims description 2
• 239000000427 antigen Substances 0.000 claims description 2
• 108091007433 antigens Proteins 0.000 claims description 2
• 102000036639 antigens Human genes 0.000 claims description 2
• 210000004027 cell Anatomy 0.000 claims description 2
• 238000010353 genetic engineering Methods 0.000 claims description 2
• 102000018358 immunoglobulin Human genes 0.000 claims description 2
• 230000002452 interceptive effect Effects 0.000 claims description 2
• 229960003301 nivolumab Drugs 0.000 claims description 2
• 239000002773 nucleotide Substances 0.000 claims description 2
• 125000003729 nucleotide group Chemical group 0.000 claims description 2
• 229960002621 pembrolizumab Drugs 0.000 claims description 2
• 229950010773 pidilizumab Drugs 0.000 claims description 2
• 229950007213 spartalizumab Drugs 0.000 claims description 2
• FKBFDTRILNZGAI-IMJSIDKUSA-N Asp-Cys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O FKBFDTRILNZGAI-IMJSIDKUSA-N 0.000 claims 1
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 201000011510 cancer Diseases 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 239000000546 pharmaceutical excipient Substances 0.000 claims 1
• 238000002965 ELISA Methods 0.000 description 2
• 102100037850 Interferon gamma Human genes 0.000 description 2
• 108010074328 Interferon-gamma Proteins 0.000 description 2
• 108010002350 Interleukin-2 Proteins 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000000126 substance Substances 0.000 description 1